Sanofi SA Announces Extension Trial Positive Effect of Multiple Sclerosis Drug Lemtrada-Reuters

Thursday, 21 Mar 2013 08:00pm EDT 

Reuters reported that Sanofi SA announced that its experimental multiple sclerosis drug Lemtrada continue to benefit the majority of patients long after they have completed their treatment. In an extension trial sponsored by the Company that followed up patients who had taken part in two late-stage studies, more than half did not experience any relapses in the first year after completing a two-course treatment with Lemtrada. Lemtrada, which is given via an intravenous drip for five days and then for three days a year later, has the potential to re-programme the immune system and could potentially change the long-term progression of the disease. The study showed that more than 80%of patients did not require a third course of Lemtrada in the first year after treatment, while more than 70% of patients showed improved or stable disability after three years. Lemtrada is under review by the European Medicines Agency and the U.S. Food and Drug Administration, which are expected to give their feedback by the end of 2013. 

Company Quote

-0.16 -0.21%
11:38am EST